NO20043290D0 - Deazapuriner og anvendelse av slike - Google Patents

Deazapuriner og anvendelse av slike

Info

Publication number
NO20043290D0
NO20043290D0 NO20043290A NO20043290A NO20043290D0 NO 20043290 D0 NO20043290 D0 NO 20043290D0 NO 20043290 A NO20043290 A NO 20043290A NO 20043290 A NO20043290 A NO 20043290A NO 20043290 D0 NO20043290 D0 NO 20043290D0
Authority
NO
Norway
Prior art keywords
inflammatory
generally
deazapurins
subclasses
autoimmune
Prior art date
Application number
NO20043290A
Other languages
English (en)
Other versions
NO20043290L (no
NO329994B1 (no
Inventor
Hiromitsu Yokohama
Kenzo Muramoto
Toshihiko Kaneko
Kouichi Kikuchi
Boris M Seletsky
Wanjun Zheng
Ieharu Hishinuma
Motohiro Soejima
Jane Daun
Heather A Davis
Bruce F Decosta
Fabian Gusovsky
Yimin Jiang
Seiichi Kobayshi
Andre Lescarbeau
Xiang-Yi Li
Norihito Ohi
Marc Pesant
Lynda Trembley
Ye Yao
Original Assignee
Usspyvee Mark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Usspyvee Mark filed Critical Usspyvee Mark
Publication of NO20043290D0 publication Critical patent/NO20043290D0/no
Publication of NO20043290L publication Critical patent/NO20043290L/no
Publication of NO329994B1 publication Critical patent/NO329994B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20043290A 2002-01-07 2004-08-06 Deazapuriner, farmasoytiske preparater som omfatter forbindelsene og eventuelt et ytterligere terapeutisk middel, samt anvendelse av forbindelsene til tilvikning av et medikament for behandling av en inflammatorisk eller autoimmun lidelse eller proliferativ lidelse NO329994B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34659802P 2002-01-07 2002-01-07
PCT/US2003/000366 WO2003057696A1 (en) 2002-01-07 2003-01-07 Deazapurines and uses thereof

Publications (3)

Publication Number Publication Date
NO20043290D0 true NO20043290D0 (no) 2004-08-06
NO20043290L NO20043290L (no) 2004-09-22
NO329994B1 NO329994B1 (no) 2011-02-07

Family

ID=23360154

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043290A NO329994B1 (no) 2002-01-07 2004-08-06 Deazapuriner, farmasoytiske preparater som omfatter forbindelsene og eventuelt et ytterligere terapeutisk middel, samt anvendelse av forbindelsene til tilvikning av et medikament for behandling av en inflammatorisk eller autoimmun lidelse eller proliferativ lidelse

Country Status (22)

Country Link
US (4) US7314936B2 (no)
EP (2) EP1707566A1 (no)
JP (1) JP4411455B2 (no)
KR (2) KR100980163B1 (no)
CN (1) CN100503608C (no)
AT (1) ATE327236T1 (no)
AU (2) AU2003235741B8 (no)
BR (1) BR0306785A (no)
CA (1) CA2472479C (no)
CY (1) CY1106138T1 (no)
DE (2) DE60305446T4 (no)
DK (1) DK1474425T3 (no)
ES (1) ES2262996T3 (no)
IL (3) IL162884A0 (no)
MX (1) MXPA04006614A (no)
NO (1) NO329994B1 (no)
NZ (2) NZ555911A (no)
PT (1) PT1474425E (no)
RU (1) RU2380368C2 (no)
SI (1) SI1474425T1 (no)
WO (1) WO2003057696A1 (no)
ZA (1) ZA200406272B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589954B1 (en) * 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
PT1474425E (pt) * 2002-01-07 2006-09-29 Eisai Co Ltd Desazapurinas e sua utilizacao
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
CN101111495B (zh) * 2005-02-02 2011-06-15 卫材R&D管理有限公司 晶体1h-咪唑并[4,5-b]吡啶-5-胺，7-[5-[(环己基甲基氨基)-甲基]-1h-吲哚-2-基]-2-甲基，硫酸盐(1:1)，三水合物及其药物用途
UY29825A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
EP2016077A2 (en) * 2006-04-25 2009-01-21 Astex Therapeutics Limited Pharmaceutical compounds
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
EP2201012B1 (en) 2007-10-11 2014-06-25 AstraZeneca AB Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors
WO2010030360A1 (en) * 2008-09-11 2010-03-18 Arena Pharmaceuticals, Inc. 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS
WO2011021678A1 (ja) * 2009-08-21 2011-02-24 武田薬品工業株式会社 縮合複素環化合物
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
CA2811025C (en) 2010-09-10 2018-07-17 Shionogi & Co., Ltd. Hetero ring-fused imidazole derivative having ampk activating effect
ES2652662T3 (es) * 2011-02-25 2018-02-05 Merck Sharp & Dohme Corp. Novedosos derivados de azabencimidazol cíclicos útiles como agentes antidiabéticos
BR112013025410A2 (pt) 2011-04-01 2016-12-20 Astrazeneca Ab tratamento terapêutico
GB201106814D0 (en) * 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
EP2733141B1 (en) * 2011-07-15 2019-01-09 Shionogi & Co., Ltd. Azabenzimidazole derivative having ampk-activating activity
WO2013079964A1 (en) 2011-11-30 2013-06-06 Astrazeneca Ab Combination treatment of cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
GB201401198D0 (en) * 2014-01-24 2014-03-12 Bial Portela & Ca Sa Process for the syntheis of substituted urea compounds
EP2913330A1 (en) 2014-02-27 2015-09-02 Laboratoire Biodim Condensed derivatives of imidazole useful as pharmaceuticals
CN104974187A (zh) * 2014-04-10 2015-10-14 吉林省博创药业有限公司 菲罗啉类衍生物及其制备方法和应用
ES2907622T3 (es) * 2014-10-06 2022-04-25 Merck Patent Gmbh Compuestos de heteroarilo como inhibidores de BTK y usos de estos
EP3562306A4 (en) 2016-12-29 2020-06-24 Selenity Therapeutics (Bermuda), Ltd. METALLOENZYME INHIBITOR COMPOUNDS
KR20190129034A (ko) * 2016-12-29 2019-11-19 세레니티 테라퓨틱스 (버뮤다), 리미티드 금속효소 억제제 화합물
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
ES2945435T3 (es) 2017-11-14 2023-07-03 Bristol Myers Squibb Co Compuestos de indol sustituidos
KR20200101402A (ko) 2017-12-19 2020-08-27 브리스톨-마이어스 스큅 컴퍼니 Tlr 억제제로서 유용한 치환된 인돌 화합물
US11427580B2 (en) 2017-12-19 2022-08-30 Bristol-Myers Squibb Company 6-azaindole compounds
BR112020011979A2 (pt) * 2017-12-19 2020-11-17 Bristol-Myers Squibb Company compostos de indol substituídos por amida úteis como inibidores de tlr
ES2965182T3 (es) 2017-12-20 2024-04-11 Bristol Myers Squibb Co Compuestos de indol sustituidos con arilo y heteroarilo
EA202091480A1 (ru) * 2017-12-20 2020-11-06 Бристол-Маерс Сквибб Компани Аминоиндольные соединения, пригодные в качестве ингибиторов tlr
SG11202005733QA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Diazaindole compounds

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3891660A (en) * 1974-02-07 1975-06-24 Squibb & Sons Inc Derivatives of 1H-imidazo{8 4,5-c{9 pyridine-7-carboxylic acids and esters
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US4939146A (en) * 1987-01-29 1990-07-03 Kramer Richard S Method for alleviating ischemic-reperfusion injury
DE3702757A1 (de) 1987-01-30 1988-08-11 Hoechst Ag Neue imidazo- und triazolo-thiadiazine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung, sowie einige bei der herstellung der genannten verbindungen gebildete zwischenprodukte
US4999365A (en) * 1987-03-20 1991-03-12 Merrell Dow Pharmaceuticals Inc. Method of reducing reperfusion injury with imidazol-2-thiones
US4877810A (en) * 1988-02-05 1989-10-31 Eastman Kodak Company Protection of heart tissue from reperfusion injury
US5632991A (en) 1988-11-14 1997-05-27 Brigham & Women's Hospital Antibodies specific for E-selectin and the uses thereof
US5002965A (en) * 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
US5298518A (en) 1989-09-29 1994-03-29 Eisai Co., Ltd. Biphenylmethane derivative and pharmacological use
US5081253A (en) 1989-12-21 1992-01-14 American Home Products Corporation Imidazo(4,5-c)pyridines as antiosteoporotic agents
SE8904355D0 (sv) 1989-12-21 1989-12-21 Perstorp Ab Medicament
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
DE59307281D1 (de) 1992-06-22 1997-10-09 Boehringer Ingelheim Kg 9-AMINO-PYRIDAZINO 4',5' : 3,4]PYRROLO- 2,1-a]ISOCHINOLINE UND DEREN VERWENDUNG FÜR DIE HERSTELLUNG VON PHARMAZEUTISCHEN ZUBEREITUNGEN
US5591835A (en) * 1992-06-29 1997-01-07 Glycomed Incorporated Substituted lactose derivatives
US5360794A (en) 1992-08-03 1994-11-01 Medicarb Inc. Disubstituted and deoxy disubstituted derivatives of α-D-mannofuranosides and β-L-gulofuranosides having anti-inflammatory and anti-proliferative activity
GB9313638D0 (en) 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5486525A (en) * 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5567711A (en) * 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6048841A (en) * 1995-11-22 2000-04-11 Darwin Discovery, Ltd. Peptidyl compounds
US5981536A (en) 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
JPH10139709A (ja) 1996-11-13 1998-05-26 Chisso Corp フェニルポリハロアルキルエーテル誘導体、これを含む液晶組成物および液晶表示素子
ATE240949T1 (de) * 1997-04-18 2003-06-15 Taiho Pharmaceutical Co Ltd Epoxysuccinamid-derivate oder ihre salze
CN1268137A (zh) 1997-07-03 2000-09-27 杜邦药品公司 治疗神经失调的咪唑并嘧啶和咪唑并吡啶
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
ATE232521T1 (de) 1998-03-27 2003-02-15 Janssen Pharmaceutica Nv Hiv hemmende pyrimidin derivate
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
WO2001000610A1 (de) 1999-06-23 2001-01-04 Aventis Pharma Deutschland Gmbh Substituierte benzimidazole
CN1222520C (zh) * 1999-08-12 2005-10-12 沃泰克斯药物股份有限公司 c－JUN N－末端激酶(JNK)和其它蛋白激酶的抑制剂
US6599741B1 (en) 1999-09-14 2003-07-29 Avontec Gmbh Modulating transcription of genes in vascular cells
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
WO2001030778A1 (en) 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use
AU2001230584A1 (en) 2000-02-09 2001-08-20 Hokuriku Seiyaku Co., Ltd. 1h-imidazopyridine derivatives
US7186683B2 (en) * 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
WO2002092573A2 (en) * 2001-05-16 2002-11-21 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
PL370766A1 (en) * 2001-12-04 2005-05-30 F.Hoffmann-La Roche Ag Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
PT1474425E (pt) * 2002-01-07 2006-09-29 Eisai Co Ltd Desazapurinas e sua utilizacao
US6861278B2 (en) * 2002-04-11 2005-03-01 Nordson Corporation Method and apparatus for underfilling semiconductor devices
CN101111495B (zh) * 2005-02-02 2011-06-15 卫材R&D管理有限公司 晶体1h-咪唑并[4,5-b]吡啶-5-胺，7-[5-[(环己基甲基氨基)-甲基]-1h-吲哚-2-基]-2-甲基，硫酸盐(1:1)，三水合物及其药物用途

Also Published As

Publication number Publication date
RU2380368C2 (ru) 2010-01-27
AU2009200689A1 (en) 2009-03-12
CN100503608C (zh) 2009-06-24
RU2004124054A (ru) 2005-04-10
BR0306785A (pt) 2004-11-09
DE60305446D1 (de) 2006-06-29
AU2003235741B8 (en) 2009-01-15
US8691814B2 (en) 2014-04-08
IL191543A0 (en) 2008-11-03
JP2005524621A (ja) 2005-08-18
KR20040077707A (ko) 2004-09-06
KR101108722B1 (ko) 2012-02-17
CA2472479C (en) 2011-10-11
NO20043290L (no) 2004-09-22
EP1474425B1 (en) 2006-05-24
KR20100066593A (ko) 2010-06-17
PT1474425E (pt) 2006-09-29
ZA200406272B (en) 2006-01-25
DE60305446T2 (de) 2007-03-08
CN1630657A (zh) 2005-06-22
IL162884A0 (en) 2005-11-20
KR100980163B1 (ko) 2010-09-03
SI1474425T1 (sl) 2006-10-31
AU2003235741A1 (en) 2003-07-24
CY1106138T1 (el) 2011-06-08
WO2003057696A1 (en) 2003-07-17
ATE327236T1 (de) 2006-06-15
IL197484A0 (en) 2009-12-24
US7868002B2 (en) 2011-01-11
US20080103137A1 (en) 2008-05-01
CA2472479A1 (en) 2003-07-17
EP1707566A1 (en) 2006-10-04
AU2003235741B2 (en) 2008-12-04
ES2262996T3 (es) 2006-12-01
EP1474425A1 (en) 2004-11-10
DK1474425T3 (da) 2006-09-25
US7314936B2 (en) 2008-01-01
EP1474425B9 (en) 2008-07-02
DE60305446T4 (de) 2009-07-09
NZ533958A (en) 2007-09-28
US20040186127A1 (en) 2004-09-23
JP4411455B2 (ja) 2010-02-10
NO329994B1 (no) 2011-02-07
NZ555911A (en) 2008-07-31
MXPA04006614A (es) 2004-10-04
US20110105427A1 (en) 2011-05-05
US20050124649A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
NO20043290D0 (no) Deazapuriner og anvendelse av slike
GEP20074148B (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
DE602004001857D1 (de) Thienopyrimidindione und deren verwendung bei der modulierung von autoimmunerkrankungen
IS6950A (is) Samsetning epóþílonhliðstæðna og efnameðferðarlyfja til meðhöndlunar frumufjölgunarsjúkdóma
IS6658A (is) Ný efnasambönd
SG146624A1 (en) Cytokine inhibitors
CY1109227T1 (el) Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων
NO20050828L (no) lndol-3-svovelderivater
DE60315677D1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
SE0302139D0 (sv) Novel compounds
ID18883A (id) Pesaing 5-ht 1f
ATE413388T1 (de) Muskarin antagonisten
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
DE602004031410D1 (de) Inden derivate als pharmazeutika
SE0101038D0 (sv) Novel compounds
WO2002068476A3 (en) Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
ATE315563T1 (de) Piperidinylmorpholinylderivate als modulatoren der aktivität des chemokinrezeptors
SE0303280D0 (sv) Novel compounds
IL173629A0 (en) Imidazo(4,5-b) pyridine derivatives and pharmaceutical compositions containing the same
SE0302755D0 (sv) Novel compounds
NO20002408D0 (no) 5-HT1F antagonister
MXPA03010259A (es) Nuevos derivados de 5-tio-ss-d-xilopiranosida, procedimiento de preparacion, composiciones farmaceuticas que los contienen y el uso terapeutico de los mismos.
MXPA05006530A (es) Derivados de 1-n-fenilamino-1h-imidazola como inhibidores aromatasa.
WO2004054983A3 (en) 1-n-phenylamino-1h-imidazole derivatives as aromatase inhibitors

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees